---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022610"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-05-13T11:30:50+00:00"
generated_at: "2026-05-13T11:38:35.171423+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abeona Q1 net product revenue $8.7M; three ZEVASKYN patients treated; in-licenses PSMA T-cell therapy

## Summary
- Net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025; net loss $17.1M ($0.30/sh).
- Cash and investments $168.3M as of March 31, 2026, down from $191.4M at year-end 2025.
- Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites including CHOP and Columbia.
- In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; IND expected H2 2027.
- Deprioritized in-house ophthalmology programs to focus on ZEVASKYN and ABO-701.

## SEC filing metadata
- accession: 0001493152-26-022610
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-05-13T11:30:50+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/0001493152-26-022610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022610
- JSON: https://secwatch.observer/filing/0001493152-26-022610.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022610.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported first quarter ended March 31, 2026 results: revenue $8.7 million, net income $(17.1) million, EPS $(0.30) per basic and diluted common share.
  - Period: first quarter ended March 31, 2026
  - Revenue: $8.7 million
  - Net income: $(17.1) million
  - EPS: $(0.30) per basic and diluted common share
  - Result: reported results
  source text: Abeona reported net product revenue of $8.7 million in the first quarter ending March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/0001493152-26-022610-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.